Alterity Therapeutics presents data on the potential of ATH434 to treat FA
The biotechnology company Alterity Therapeutics presented data from their lead Friedreich’s ataxia (FA) drug candidate ATH434 at the 2024 US World Orphan Drug Congress. In FA, a genetic change in […]
Alterity Therapeutics presents data on the potential of ATH434 to treat FA Read More »